Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 15/20 | 0.43 |
| ▸ | MARK3 | P27448 | 2/20 | 0.41 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.40 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.39 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522947 | 1.00 | PLK1 (0.43) | PLK1MARK3MARK4BRD4BRDT | |
| SCHEMBL523486 | 0.92 | PLK1 (0.44) | PLK1MARK3MARK4BRD4BRDT | |
| SCHEMBL523147 | 0.92 | PLK1 (0.44) | PLK1MARK3MARK4BRD4BRDT | |
| SCHEMBL522769 | 0.91 | PLK1 (0.41) | PLK1MARK3MARK4BRD4BRDT | |
| SCHEMBL522770 | 0.91 | PLK1 (0.41) | PLK1MARK3MARK4BRD4BRDT | |
| SCHEMBL522605 | 0.89 | IDH1 (0.45) | PLK1MARK3MARK4BRD4BRDT | |
| SCHEMBL522384 | 0.89 | IDH1 (0.45) | PLK1MARK3MARK4BRD4BRDT | |
| SCHEMBL522256 | 0.84 | PLK1 (0.42) | PLK1MARK3MARK4BRD4BRDT | |
| SCHEMBL12694742 | 0.84 | PLK1 (0.42) | PLK1MARK3MARK4BRD4BRDT | |
| SCHEMBL2396321 | 0.84 | PLK1 (0.46) | PLK1MARK3MARK4BRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322793-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-20 | — | — | US | claimed |
| US-8278297-B2 | Protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | claimed |
| US-20120028966-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | claimed |
| EP-2356122-A1 | PROTEIN KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2011-08-17 | — | — | EP | claimed |
| WO-2010008454-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | WO | claimed |
| EP-2356122-B1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-2480550-B1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-10 | — | — | EP | disclosed |
| US-8618106-B2 | Protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120322793-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120271045-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-25 | — | — | US | disclosed |
| US-8278297-B2 | Protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120028966-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2356122-A1 | PROTEIN KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010008454-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120271045-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | DCK, MAP3K5, MAP3K1 | PLK1 42/4885MARK3 378/4885MARK4 336/4885 |
| US-20120322793-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PLK1 86/4885MARK3 267/4885MARK4 250/4885 |
| US-20120028966-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PLK1 86/4885MARK3 267/4885MARK4 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.